Tosoh Bioscience, a leading name in the biotechnology sector, is headquartered in Great Britain and operates extensively across Europe, Asia, and North America. Founded in 2003, the company has established itself as a key player in the development and manufacturing of high-quality chromatography products and bioprocessing solutions. With a focus on innovative technologies, Tosoh Bioscience offers a diverse range of core products, including affinity chromatography resins and analytical instruments, which are renowned for their reliability and performance. The company’s commitment to quality and customer satisfaction has solidified its market position, making it a trusted partner for laboratories and biopharmaceutical manufacturers worldwide. Notable achievements include significant advancements in protein purification and a robust portfolio that supports the evolving needs of the life sciences industry.
How does Tosoh Bioscience's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Tosoh Bioscience's score of 34 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Tosoh Bioscience reported total carbon emissions of approximately 78,887.3 kg CO2e. This figure includes 23,999.8 kg CO2e from Scope 1 emissions, which are primarily attributed to mobile combustion. Notably, Scope 2 emissions were reported as zero, while Scope 3 emissions accounted for about 54,887.5 kg CO2e, with significant contributions from business travel (20,778.6 kg CO2e) and downstream transportation and distribution (30,748.4 kg CO2e). Comparatively, in 2021, the company’s total emissions were significantly higher at approximately 369,111.9 kg CO2e, with Scope 1 emissions at 316,972.3 kg CO2e and Scope 2 emissions at 4,458.9 kg CO2e. Scope 3 emissions for that year were about 47,680.7 kg CO2e. Tosoh Bioscience has set an ambitious commitment to achieve net zero emissions by 2045, aiming for a reduction of 90% across all scopes. This long-term target reflects the company's dedication to sustainability and climate action, as outlined in their Carbon Reduction Plan. The emissions data is not cascaded from any parent organization, indicating that these figures are specific to Tosoh Bioscience Limited.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | |
|---|---|---|
| Scope 1 | 316,972.3 | 00,000.0 |
| Scope 2 | 4,458.9 | - |
| Scope 3 | 47,680.7 | 00,000.0 |
Tosoh Bioscience's Scope 3 emissions, which increased by 15% last year and increased by approximately 15% since 2021, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 70% of total emissions under the GHG Protocol, with "Downstream Transportation & Distribution" being the largest emissions source at 56% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Tosoh Bioscience has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
